27th Jan 2026 07:00
hVIVO plc
("hVIVO", the "Company" or the "Group")
Notice of Trading Update
hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, confirms that it will issue a trading update for the year ended 31 December 2025 on Thursday 29 January 2026.
Investor presentation
Yamin 'Mo' Khan, Chief Executive Officer, and Stephen Pinkerton, Chief Financial Officer, will provide a live presentation relating to the trading update via the Investor Meet Company platform on Thursday 29 January 2026 at 6pm.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet hVIVO here. Investors who already follow hVIVO on the Investor Meet Company platform will automatically be invited.
For further information please contact:
hVIVO plc | +44 (0)20 7756 1300 | |||
Yamin 'Mo' Khan, Chief Executive Officer Stephen Pinkerton, Chief Financial Officer | ||||
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker) | +44 (0)20 7220 0500 | |||
Geoff Nash, Callum DavidsonTrisyia Jamaludin, Harriet Ward Nigel Birks - Life Science Specialist Sales Louise Talbot - Sales | ||||
Peel Hunt LLP (Joint Broker) | +44 (0)20 7418 8900 | |||
James Steel, Dr Christopher Golden | ||||
Davy (Joint Broker) | +353 (0) 1 679 6363 | |||
Anthony Farrell, Niall Gilchrist | ||||
ICR Healthcare (Financial PR & IR) Mary-Jane Elliott / Stephanie Cuthbert / Phillip Marriage / Louis Ashe-Jepson
| ||||
Notes to Editors
hVIVO plc (Ticker: HVO) is full-service Contract Research Organisation (CRO) and the global leader in human challenge trials. The company delivers end-to-end clinical development services to a diverse and expanding client base, including seven of the world's ten largest biopharma companies.
hVIVO specialises in conducting human challenge trials across multiple infectious and respiratory indications, leveraging its state-of-the-art quarantine facility in London-the largest of its kind worldwide. The company also offers comprehensive virology and immunology laboratory services under the hLAB brand.
Through its German subsidiary, CRS, hVIVO operates a 120-bed capacity across Mannheim and Kiel, providing early-phase clinical trial services, including first-in-human and proof-of-concept studies. Its second subsidiary, Venn Life Sciences, offers Early Drug Development Consulting and Biometry services to the biopharma sector.
The Group provides fully integrated drug development solutions from preclinical stages through Phase II trials, alongside patient recruitment via FluCamp. Additionally, its five clinical sites support outpatient Phase II and III trials, ensuring a seamless and efficient pathway from discovery to late-stage development.
Related Shares:
hVIVO